SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Commercial Services

Read more breaking news

 

 
News in brief

Quintiles to promote Almirall's COPD drug in UK

30-Jul-2012

Spanish pharmaceutical firm Almirall has called on Quintiles to help promote its respiratory drug portfolio in the UK.

The marketing deal will include Eklira Genuair, a new long-acting antimuscarinic (LAMA) obstructive pulmonary disease (COPD) developed by Almirall which was approved by European regulators last week

The agreement - terms of which were not disclosed - builds on the firms’ existing relationship that has seen Quintiles play a part in European clinical trials of the drug and provide market access service in a range of countries.

The growing market access and commercialisation services sector has been a particularly active area for Quintiles so far this year.

Since January the pharma services firm has expanded its commercialisation business to North Africa and the Middle East , signed a deal to support Delcath’s efforts in Europe and established a commercial solutions unit in Brazil .

It is unclear if Quintiles will play a role in promoting Eklira Genuai in the US – where it will be sold by Almirall’s partner Forest Laboratories as Tudorza Pressair having been cleared by the US Food and Drug Administration (FDA) earlier this month.